A panel of experts discuss ADC-based treatment strategies in HR+ Breast cancer.
Sara A. Hurvitz, MD, FACP
Advertisement
Sara A. Hurvitz, MD, FACP, is a medical oncologist, senior vice president, professor in, and director of the Clinical Research Division at Fred Hutchinson Cancer Center in Seattle, Washington. She also serves as the Smith Family Endowed Chair in Women’s Health.
Articles by Sara A. Hurvitz, MD, FACP
A panel of experts discuss treatment advancements targeting the PI3K/AKT pathway in HR+ Breast Cancer.
A panel of experts discuss navigating 2L treatment strategies.
A panel of experts offer perspectives in navigating treatment strategies with CDK4/6 inhibitors.
A panel of experts discuss treatment updates in regards to CDK4/6 inhibitors.
A panel of experts discuss the potential of individual tumor sequencing with bespoke testing methodologies.
A panel of experts give perspectives on optimizing biomarker testing in Advanced HR+/HER2- Breast Cancer.
A panel of experts discuss advancements in adjuvant therapy for early-stage breast cancer.
Expert breast oncologists examine adjuvant therapy approaches for early-stage hormone receptor-positive breast cancer, emphasizing the distinct treatment strategies and outcomes observed in pre- and post-menopausal patient populations.
Leading oncologists explore optimal biomarker testing strategies for early-stage breast cancer, examining the comparative advantages of tissue and liquid biopsies to guide personalized treatment decisions.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5